<?xml version="1.0" encoding="UTF-8"?>
<results title="country">
 <result pre="2020 ManickamCordelia1http://orcid.org/0000-0002-5187-423XSugawaraSho1http://orcid.org/0000-0003-3157-2557ReevesR. Keith12*[1], Center for Virology and Vaccine Research, Beth" exact="Israel" post="Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United"/>
 <result pre="Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts," exact="United States" post="of America[2], Ragon Institute of Massachusetts General Hospital, MIT,"/>
 <result pre="Institute of Massachusetts General Hospital, MIT, and Harvard, Cambridge, Massachusetts," exact="United States" post="of AmericaHobmanTom C.Editor[], University of Alberta, CANADA The authors"/>
 <result pre="could prove beneficial against COVID-19. Clinical studies are underway in" exact="the Netherlands" post="and Australia (ClinicalTrials.gov Identifier: NCT04327206 and NCT04328441) to test"/>
 <result pre="prove beneficial against COVID-19. Clinical studies are underway in the" exact="Netherlands" post="and Australia (ClinicalTrials.gov Identifier: NCT04327206 and NCT04328441) to test"/>
 <result pre="against COVID-19. Clinical studies are underway in the Netherlands and" exact="Australia" post="(ClinicalTrials.gov Identifier: NCT04327206 and NCT04328441) to test the efficacy"/>
 <result pre="for COVID-19 patients with severe pneumonia is also underway in" exact="China" post="[78] (NCT04264533). Functional exhaustion of NK cells and T"/>
 <result pre="T cells responses [86]. A randomized Phase II trial in" exact="Hong Kong" post="showed viral clearance in patients with mild and moderate"/>
 <result pre="estimates of comorbidities affecting risk for complications from COVID-19 in" exact="the US." post="202010.1101/2020.03.30.20043919 17WanS, YiQ, FanS, LvJ, ZhangX, GuoL, et al.Relationships"/>
</results>
